Delisted from NASDAQ in Apr 2023
SRNE - Sorrento Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
SRNE price evolution
SRNE
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $70.69 | $70.34 | $111.91 | $36.66 |
| Short term investments | $47.17 | $63.26 | $158.75 | $90.22 |
| Net receivables | $24.19 | $24.71 | $24.67 | $18.71 |
| Inventory | $17.96 | $20.7 | $14.09 | $8.11 |
| Total current assets | $176.96 | $196.05 | $331.12 | $172.99 |
| Long term investments | $55.6 | $50.74 | $50.67 | $51.27 |
| Property, plant & equipment | $128.9 | $128.62 | $126.6 | $126.5 |
| Goodwill & intangible assets | $251.64 | $253.92 | $338.2 | $339.23 |
| Total noncurrent assets | $438.66 | $436.08 | $524.52 | $521.83 |
| Total investments | $102.78 | $114 | $209.42 | $141.49 |
| Total assets | $615.61 | $632.13 | $855.64 | $694.82 |
| Current liabilities | ||||
| Accounts payable | $38.39 | $24.94 | $25.02 | $27.41 |
| Deferred revenue | $117.5 | $118.46 | $118.34 | $120.05 |
| Short long term debt | $66.28 | $37.22 | $69.39 | $43.52 |
| Total current liabilities | $201.98 | $145.32 | $204.23 | $139.45 |
| Long term debt | $101.93 | $167.38 | $179.49 | $194.06 |
| Total noncurrent liabilities | $283.43 | $351.05 | $425.21 | $477.24 |
| Total debt | $168.21 | $204.61 | $248.88 | $237.58 |
| Total liabilities | $485.41 | $496.37 | $629.44 | $616.69 |
| Shareholders' equity | ||||
| Retained earnings | -$1735.76 | -$1646.18 | -$1427.42 | -$1386.6 |
| Other shareholder equity | $0.23 | $0.84 | -$0.22 | $1.03 |
| Total shareholder equity | $131.85 | $132.02 | $226.54 | $78.75 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.66 | $56.46 | $80.77 | $213.33 |
| Short term investments | $90.22 | $0.3 | ||
| Net receivables | $18.71 | $15.51 | $14.45 | $3.83 |
| Inventory | $8.11 | $1.83 | $3.36 | $2.9 |
| Total current assets | $172.99 | $86.23 | $67.59 | $179.56 |
| Long term investments | $51.27 | $256.4 | $262.24 | $264.99 |
| Property, plant & equipment | $126.5 | $73.91 | $76.27 | $24.38 |
| Goodwill & intangible assets | $339.23 | $117.23 | $101.61 | $104.58 |
| Total noncurrent assets | $521.83 | $449.59 | $490.04 | $444.52 |
| Total investments | $141.49 | $256.4 | $262.24 | $265.29 |
| Total assets | $694.82 | $535.82 | $557.63 | $624.09 |
| Current liabilities | ||||
| Accounts payable | $27.41 | $25.1 | $28.54 | $25.13 |
| Deferred revenue | $120.05 | $117.67 | $118.03 | $118.98 |
| Short long term debt | $43.52 | $26.83 | $39.58 | $10.15 |
| Total current liabilities | $139.45 | $96.48 | $115.21 | $61.62 |
| Long term debt | $194.06 | $142.56 | $251.2 | $223.14 |
| Total noncurrent liabilities | $477.24 | $298.61 | $409.67 | $354.97 |
| Total debt | $237.58 | $169.39 | $290.78 | $233.29 |
| Total liabilities | $616.69 | $395.09 | $524.88 | $416.59 |
| Shareholders' equity | ||||
| Retained earnings | -$1386.6 | -$958.28 | -$659.82 | -$367.75 |
| Other shareholder equity | $1.03 | $0.52 | -$0.27 | $0.01 |
| Total shareholder equity | $78.75 | $165.15 | $78.59 | $209.47 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $17.4 | $11.46 | $18.39 | $13.08 |
| Cost of revenue | $8.27 | $5.7 | $5.76 | $3.14 |
| Gross Profit | $9.13 | $5.76 | $12.63 | $9.94 |
| Operating activities | ||||
| Research & development | $67.99 | $48.47 | $63.98 | $59.13 |
| Selling, general & administrative | $50.16 | $48.14 | $44.33 | $54.58 |
| Total operating expenses | $118.58 | $124.12 | $121.61 | $124.55 |
| Operating income | -$109.44 | -$118.36 | -$108.98 | -$114.61 |
| Income from continuing operations | ||||
| EBIT | -$89.8 | -$217.5 | -$36.1 | -$174.53 |
| Income tax expense | -$1.01 | -$1.05 | $1.46 | -$33.05 |
| Interest expense | $0.79 | $2.31 | $3.25 | $2.94 |
| Net income | ||||
| Net income | -$89.58 | -$218.76 | -$40.81 | -$144.42 |
| Income (for common shares) | -$89.58 | -$218.76 | -$40.81 | -$144.42 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $52.9 | $39.99 | $31.43 | $21.19 |
| Cost of revenue | $13.03 | $9.94 | $12.24 | $7.06 |
| Gross Profit | $39.87 | $30.05 | $19.2 | $14.13 |
| Operating activities | ||||
| Research & development | $206.92 | $111.34 | $106.88 | $76.96 |
| Selling, general & administrative | $196.86 | $116.18 | $103.56 | $63.64 |
| Total operating expenses | $441.32 | $274.56 | $278.59 | $164.56 |
| Operating income | -$401.45 | -$244.52 | -$259.39 | -$150.43 |
| Income from continuing operations | ||||
| EBIT | -$451.62 | -$280.29 | -$256.4 | -$152.18 |
| Income tax expense | -$33.52 | -$2.01 | -$0.47 | -$6.27 |
| Interest expense | $10.22 | $20.18 | $36.14 | $57.63 |
| Net income | ||||
| Net income | -$428.32 | -$298.46 | -$292.07 | -$203.54 |
| Income (for common shares) | -$428.32 | -$298.46 | -$292.07 | -$203.54 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$89.58 | -$218.76 | -$40.81 | -$144.42 |
| Operating activities | ||||
| Depreciation | $4.18 | $4.42 | $4.29 | $3.66 |
| Business acquisitions & disposals | -$4.26 | $0.98 | -$11.07 | -$0.65 |
| Stock-based compensation | $18.5 | $18.32 | $20.79 | $22.68 |
| Total cash flows from operations | -$61.17 | -$80.99 | -$83.36 | -$72.14 |
| Investing activities | ||||
| Capital expenditures | -$3.83 | -$2.71 | -$2.59 | -$2.21 |
| Investments | $0.65 | |||
| Total cash flows from investing | -$8.09 | -$1.73 | -$13.66 | -$2.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $71.47 | $104.82 | $164.56 | $69.11 |
| Net borrowings | $0.02 | -$63.05 | $8.8 | $1.75 |
| Total cash flows from financing | $71.5 | $41.77 | $173.37 | $70.86 |
| Effect of exchange rate | -$1.89 | -$0.62 | -$1.1 | $0.41 |
| Change in cash and equivalents | $2.23 | -$40.95 | $76.34 | -$3.48 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$428.32 | -$298.46 | -$292.07 | -$203.54 |
| Operating activities | ||||
| Depreciation | $16.32 | $14.71 | $15.04 | $9.05 |
| Business acquisitions & disposals | -$36.05 | -$2.34 | -$26.73 | -$10 |
| Stock-based compensation | $90.19 | $31.42 | $12.65 | $6.21 |
| Total cash flows from operations | -$281.82 | -$159.54 | -$173 | -$111.77 |
| Investing activities | ||||
| Capital expenditures | -$8.87 | -$6.53 | -$11.44 | -$11.2 |
| Investments | $124.77 | |||
| Total cash flows from investing | $79.85 | -$39.92 | -$38.17 | -$21.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $217.25 | $416.22 | $47.7 | $83.82 |
| Net borrowings | -$35.91 | -$186.98 | $22.34 | $273.38 |
| Total cash flows from financing | $181.33 | $174.24 | $78.89 | $326 |
| Effect of exchange rate | $0.84 | $0.92 | -$0.28 | -$0.14 |
| Change in cash and equivalents | -$20.64 | -$25.22 | -$132.28 | $193.04 |
News
Fundamentals
| Market cap | $153.05M |
|---|---|
| Enterprise value | $250.58M |
| Shares outstanding | 460.72M |
| Revenue | $60.32M |
|---|---|
| EBITDA | -$501.38M |
| EBIT | -$517.93M |
| Net Income | -$493.57M |
| Revenue Q/Q | 44.25% |
| Revenue Y/Y | 17.51% |
| P/E ratio | -0.31 |
|---|---|
| EV/Sales | 4.15 |
| EV/EBITDA | -0.50 |
| EV/EBIT | -0.48 |
| P/S ratio | 2.54 |
| P/B ratio | 1.16 |
| Book/Share | 0.29 |
| Cash/Share | 0.15 |
| EPS | -$1.07 |
|---|---|
| ROA | -70.55% |
| ROE | -346.87% |
| Debt/Equity | 7.83 |
|---|---|
| Net debt/EBITDA | -0.83 |
| Current ratio | 0.88 |
| Quick ratio | 0.79 |